General information

Announcements(0)

Program

Sessions

Search presentations

Timetable

Wed. Dec 3, 2025

Thu. Dec 4, 2025

Fri. Dec 5, 2025

web_header_en.png

web_icon.png

Profile management

Announcements

Bookmark

Download PDF for print

Program Type

Login required to view

Password required to view

Presentation Information

Session Details

Please enter the password printed on your name card.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Illumina innovation roadmap

Advancing Multi-omics: Emerging Illumina Technologies and Proteome Biomarker Discovery

Illumina is driving the development of technologies that enable multi-omics analysis.<br>In this seminar, we will introduce key next-generation technologies and welcome Professor Koichi Matsuda from the University of Tokyo and Biobank Japan, who will present on “Comparative Analysis of Proteome Assays and Disease Biomarker Discovery Research.”<br>Abstract: In recent years, large-scale proteomic and metabolomic analyses have been increasingly implemented to facilitate genome-based drug discovery. Internationally, initiatives such as the UK Biobank have advanced analyses encompassing up to 500,000 participants. For proteome profiling, commercial platforms such as Somascan, which employs RNA aptamers coupled with array technology, and Olink HT, based on the proximity extension assay (PEA), have been widely utilized in large-scale biobanks. More recently, Illumina has developed a novel proteomic system (IPP) that incorporates barcode sequences attached to RNA aptamers. To enable cross-platform evaluation, we analyzed 75 identical plasma samples using a pre-commercial prototype of the IPP, in parallel with the Olink HT and Somascan systems. In this seminar, I will present the results of this comparative validation, and further highlight our ongoing biomarker discovery studies utilizing Biobank Japan samples, focusing on cancer and related underlying conditions.

The 48th Annual Meeting of the Molecular Biology Society of Japan

Presentation Information

[1BT-15-01]Illumina innovation roadmap

Comment